Apogee Therapeutics (NASDAQ:APGE) solidified its clinical roadmap for 2026 on Monday, reporting a year-end cash position of $902.9 million.
The San Francisco-based biotech, which is developing a suite of long-acting biologics for inflammatory and immunology (I&I) markets, confirmed that its current liquidity is sufficient to fund operations into the second half of 2028, covering several high-impact data readouts.
The company’s primary focus remains zumilokibart (APG777), an anti-IL-13 antibody designed with an extended half-life to allow for dosing as infrequent as once every three to six months.
Management confirmed that the 52-week maintenance data from the APEX Phase 2 Part A trial is expected this month, followed by the Part B 16-week induction readout in the second quarter of 2026.
If data remains positive, Apogee plans to initiate a global Phase 3 program for atopic dermatitis in the second half of the year.
Beyond its lead asset, Apogee is aggressively advancing its combination portfolio.
The company expects to report results from a Phase 1b head-to-head study in the second half of 2026 comparing APG279 (a combination of zumilokibart and an OX40L inhibitor) against the current standard of care, Dupixent.
Additionally, following positive interim Phase 1b results in asthma reported earlier this year, the company is preparing for further expansion trials in eosinophilic esophagitis (EoE).
Financially, Apogee reported a net loss of $255.8 million for 2025, or $(4.22)$ per share, compared to a loss of $182.1 million in 2024.
The wider loss reflects a significant ramp-up in R&D spending, which rose to $214.7 million as the company accelerated enrollment for its APEX trials and scaled up manufacturing capabilities to support potential commercialization.